Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2025 08:00 ET | Source: ABLi Therapeutics

ABLi Therapeutics Reports Final Results from the Phase 2 ‘201 Trial’ Evaluating Risvodetinib for the Treatment of Parkinson’s Disease

Risvodetinib demonstrated to be safe and well-tolerated with preliminary clinical benefits Risvodetinib demonstrated to be the first treatment to reduce alpha-synuclein pathology, widely recognized...
September 15, 2025 08:00 ET | Source: ABLi Therapeutics

ABLi Therapeutics to Present “Clinical Breakthrough Lecture” at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

ATLANTA and BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine...
May 28, 2025 08:00 ET | Source: ABLi Therapeutics

ABLi Therapeutics Strengthens Leadership Team and Board of Directors

Directors Appointed from Senior Leadership Teams of J&J and Atalanta Appointment of Chief Operating Officer Continues Building of Neuroscience Focused Team of Accomplished Professionals ...
May 21, 2025 08:30 ET | Source: ABLi Therapeutics

ABLi Therapeutics Announces Details of the End of Phase 2 Meeting with FDA for Evaluation of Risvodetinib as a Treatment for Parkinson’s Disease

Agency supports primary and novel secondary and exploratory endpoints proposed for Phase 3 Trial(s) Opportunity to utilize time-to-delay of levodopa/carbidopa initiation as an endpoint to measure...
May 12, 2025 08:05 ET | Source: ABLi Therapeutics

ABLi Therapeutics Launches with a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases

Lead candidate Risvodetinib (ABLi-148009) is an oral, once-daily, potent, brain-penetrant, selective c-Abl kinase inhibitor that is the first to drive clearance of disease pathology in human...